A practical reference on MC1R: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-08-14. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
| Property | Value | Notes |
|---|---|---|
| Solid-state storage | -20 degrees Celsius or lower | Desiccated and protected from light |
| Solution stability | Short and method-dependent | Confirm by stability testing |
| Purity assessment | Reversed-phase HPLC | Reported as area percent |
| Identity confirmation | LC-MS or comparable method | Mass match against expected value |
| Common synonyms | MT-II; melanotan II | Informal and catalogue names |
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
The proportion of AST to ALT in hepatocytes is about 2.5:1, but because AST is removed from serum by the liver sinusoidal cells twice as quickly (serum half-life t1/2 = 18 hr) compared to ALT (t1/2 = 36 hr), so the resulting serum levels of AST and ALT are about equal in healthy individuals, resulting in a normal AST/ALT ratio around 1. An AST/ALT ratio >5 necessarily involves extrahepatic tissue, as death of hepatocytes alone would produce an AST/ALT ratio no greater than 2.5. Because the primary cause is extrahepatic, typically an isolated elevated AST is seen, with no change in ALT. Common causes include bone disease, chronic renal failure, lymphoma, and congestive heart failure. When hepatocellular death is increased beyond the usual "background" levels, the serum levels of AST compared to ALT tend to reflect the cellular proportions, yielding AST that is over twice as prevalent as ALT (AST/ALT >2) in conditions with chronic, constant hepatocyte damage (such as alcoholic hepatitis, hepatocellular carcinoma) and during early-stage acute liver damage (such as viral hepatitis). In late-stage acute liver damage, the body has had adequate time to clear AST, but not ALT, often resulting in an AST/ALT <1. Since testing typically occurs late in acute viral hepatitis, it is conventionally associated with an AST/ALT ratio <1, though early in the disease, the AST/ALT ratio is often elevated. As the acute liver damage resolves, the body has more time to clear ALT, so in the absence of chronic liver disease, the AST/ALT ratio gradually returns to baseline levels.
Rational protein design techniques must be able to discriminate sequences that will be stable under the target fold from those that would prefer other low-energy competing states. Thus, protein design requires accurate energy functions that can rank and score sequences by how well they fold to the target structure. At the same time, however, these energy functions must consider the computational challenges behind protein design. One of the most challenging requirements for successful design is an energy function that is both accurate and simple for computational calculations. The most accurate energy functions are those based on quantum mechanical simulations. However, such simulations are too slow and typically impractical for protein design. Instead, many protein design algorithms use either physics-based energy functions adapted from molecular mechanics simulation programs, knowledge based energy-functions, or a hybrid mix of both. The trend has been toward using more physics-based potential energy functions. Physics-based energy functions, such as AMBER and CHARMM, are typically derived from quantum mechanical simulations, and experimental data from thermodynamics, crystallography, and spectroscopy. These energy functions typically simplify physical energy function and make them pairwise decomposable, meaning that the total energy of a protein conformation can be calculated by adding the pairwise energy between each atom pair, which makes them attractive for optimization algorithms.
== Side effects == Adverse drug reactions most commonly associated with loperamide are constipation (which occurs in 1.7–5.3% of users), dizziness (up to 1.4%), nausea (0.7–3.2%), and abdominal cramps (0.5–3.0%). Rare, but more serious, side effects include toxic megacolon, paralytic ileus, angioedema, anaphylaxis/allergic reactions, toxic epidermal necrolysis, Stevens–Johnson syndrome, erythema multiforme, urinary retention, and heat stroke. The most frequent symptoms of loperamide overdose are drowsiness, vomiting, and abdominal pain, or burning. High doses may result in heart problems such as abnormal heart rhythms.
Brazilian roads are the primary carriers of freight and passenger traffic. The road system totaled 2,000,000 km (1,242,742 mi) in 2023, ranking fourth largest by size globally. The total of paved roads increased from 35,496 km (22,056 mi) in 1967 to 215,000 km (133,595 mi) in 2018. Brazil's railway system has been declining since 1945, when emphasis shifted to highway construction. The country's total railway track length was 30,576 km (18,999 mi) in 2015, as compared with 31,848 km (19,789 mi) in 1970, making it the ninth largest network in the world. Most of the railway system belonged to the Federal Railroad Network Corporation (RFFSA), which was privatized in 2007. The São Paulo Metro began operating on 14 September 1974 as the first underground transit system in Brazil. There are over 4,900 airports and airfields in Brazil, second only to the United States. São Paulo–Guarulhos International Airport, near São Paulo, is the largest and busiest airport with nearly 43 million passengers annually, while handling the vast majority of commercial traffic for the country. For freight transport, waterways are of importance. The industrial zones of Manaus can be reached only by means of the Solimões–Amazonas waterway (3,250 kilometers or 2,020 miles in length, with a minimum depth of six meters or 20 feet). The country also has 50,000 kilometers (31,000 miles) of waterways. Coastal shipping links widely separated parts of the country. Bolivia and Paraguay have been given free ports at Santos.
=== Political === Immediately following the arrests, strong reactions of condemnation of Vice-President Kaili came from around the European Union. After the story was first reported by Belgian media, the President of the European Parliament, Roberta Metsola, stated that the European Parliament had been complying with an ongoing investigation, without specifying its nature. Immediately following the arrests, both PASOK, Kaili's political party in Greece, and the Socialists and Democrats Group inside the European Parliament announced Kaili's suspension from their respective parties. Two days following the arrests, Metsola suspended Kaili's responsibilities and powers as a Vice-President of the European Parliament. Three days later, in a vote of the full chamber, Kaili was officially removed as vice president by a supermajority. At the opening of the first meeting of the European Parliament following the raids, on 12 December President Metsola announced that all work with Qatar would be suspended. The suspension of Parliamentary business at such a time was significant as it comes just three days before the Parliament was due to vote on introducing a visa-free travel agreement with Qatar and other countries. This resulted in the vote on visa-free travel to Ecuador, Kuwait, and Oman also being cancelled. In addition, a major and controversial air transit agreement that would have allowed Qatar Airways unlimited access to the EU market was put on hold after warning that Qatar may have interfered in Parliament's internal deliberations on the agreement.
Sources: en.wikipedia.org
=== Duplicate private keys === Collision (two or more wallets having the same private key) is theoretically possible, since keys can be generated without being used for transactions, and are therefore offline until recorded in the blockchain ledger. However, this possibility is effectively negated because the theoretical probability of two or more private keys being the same is extremely low. The number of possible wallets and thus private keys is extremely high, so duplicating or hacking a certain key would be inconceivable.
The development of microbial therapeutics is an active area of research in microbiology and synthetic biology. Researchers generally follow two main approaches. One approach focuses on identifying naturally occurring microorganisms that already have beneficial effects on human health and studying how they can be safely used as treatments. The second approach involves genetically engineering microorganisms to give them new or enhanced therapeutic functions, such as producing specific medicines inside the body or responding to changes in the disease environment. Developing microbial therapeutics also involves addressing challenges related to safety, stability, and control. Scientists work to ensure that therapeutic microbes behave predictably, can be reliably manufactured, and remain effective without causing harm to patients.
There is a general chain of events that applies to infections, sometimes called the chain of infection or transmission chain. The chain of events involves several steps – which include the infectious agent, reservoir, entering a susceptible host, exit and transmission to new hosts. Each of the links must be present in a chronological order for an infection to develop. Understanding these steps helps health care workers target the infection and prevent it from occurring in the first place.
=== Labour Party === In 1965, Hitchens joined the Labour Party on the very first day he was eligible to vote, but along with the majority of the Labour students' organization was expelled in 1967, because of what Hitchens called "Prime Minister Harold Wilson's contemptible support for the war in Vietnam". Since then he stated he had "re-enlisted a few times" back into the Labour Party. In a 2001 interview with Reason, he said that, in 1979, despite being a member of the Labour Party, he wasn't going to vote for them, nor could he bring himself to "vote Conservative." He abstained from voting. Hitchens stated that by not voting for the Labour Party he was effectively voting for Margaret Thatcher to win, which he said he had "secretly hoped would happen." In a 2005 Vanity Fair article, he endorsed Tony Blair in the 2005 general election, mainly due to his support for the 2003 invasion of Iraq. In a 2009 Slate article, he described that in the late 1970s the Labour Party moved to the right and stated that the downfall of the Labour Party came about upon Gordon Brown's becoming Prime Minister.
Laboratory stewardship is an approach to improving the appropriate use of clinical laboratory services, including the ordering, retrieval, and interpretation of laboratory tests. It seeks to improve the value of laboratory services by balancing the quality and clinical utility of testing against its costs, rather than simply reducing the number of tests performed. Laboratory stewardship may address both overuse and underuse of laboratory testing, with the aim of reducing low-value testing while increasing the use of clinically appropriate testing. Inappropriate laboratory testing can contribute to diagnostic errors, unnecessary phlebotomy, false positive results, delays in appropriate testing, and cascades of additional investigations, and waste of healthcare resources, while underuse can delay diagnosis and treatment. Studies have estimated that approximately 10–30% of laboratory tests may be unnecessary or inappropriate. Routine blood collection can also cause discomfort and sleep disruption, and repeated phlebotomy can contribute substantially to blood loss in some hospitalized patients. Errors in ordering, retrieving, or interpreting laboratory tests can contribute to delayed or incorrect diagnoses, inappropriate treatment, and other adverse outcomes. Laboratory stewardship therefore forms part of quality improvement and patient safety efforts in laboratory medicine.
Sources: en.wikipedia.org
Laboratory confirmation typically combines retention time matching on a chromatographic system with mass measurement. A reference standard of known identity is needed for a meaningful comparison. Sequence-level techniques can add further confirmation.
There is no single harmonised standard governing these products, and manufacturing conditions differ. Impurities may include truncated sequences, oxidation products, residual solvents, and counter-ions. Independent testing is often the only way to characterise a given lot.
Reported studies have looked at pigmentation, photoprotection, and metabolic or appetite-related endpoints in small experimental settings. Much of the evidence base is early-stage and limited in size. Questions about long-term effects and clinical relevance remain open.
No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.